Neosquamous epithelium does not typically arise from Barrett's epithelium

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1701-1706

  Paulson, Thomas G ^a   Xu, Lianjun ^a   Sanchez, Carissa ^a   Blount, Patricia L ^a,b   Ayub, Kamran ^a   Odze, Robert D ^b   Reid, Brian J ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53;

AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICRODISSECTION; PRIORITY JOURNAL; SQUAMOUS EPITHELIUM;

AGED; BARRETT ESOPHAGUS; BASE SEQUENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; EPITHELIUM; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICRODISSECTION; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645697460     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1810     Document Type: Article

References (37)

1. Boyce HW, Boyce GA. Esophagus: anatomy and structural anomalies. In: Yamada T, editor. Textbook of gastroenterology. 4th ed. vol. 1. Philadelphia: Lippincott Williams & Wilkins: 2003. p. 1148-65.
2. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
3. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-56.
4. Orlando RC. Pathogenesis of reflux esophagitis and Barrett's esophagus. Med Clin North Am 2005;89:219-41.
5. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy 1993;13:46-59.
6. +)ATPaSe. Nature 1981;290:159-61.
7. Hameeteman W, Tytgat GN. Healing of chronic Barrett ulcers with omeprazole. Am J Gastroenterol 1986;81:764-6.
8. Biddlestone LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239-45.
9. Berenson MM, Johnson TD, Markowitz NR, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 1993;104:1686-91.
10. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-8.
11. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-8.
12. Low DE, Levine DS, Dail DH, Kozarek RA. Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999;94:80-5.
13. Garewal H, Ramsey L, Sharma P, Kraus K, Sampliner R, Fass R. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol 1999;94:2829-33.
14. Wang KK, Sampliner RE. Mucosal ablation therapy of Barrett esophagus. Mayo Clin Proc 2001;76:433-7.
15. Haag S, Nandurkar S, Talley NJ. Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc 1999;50:229-40.
16. Hornick JL, Blount PL, Sanchez CA, et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. Am J Surg Pathol 2005;29:372-80.
17. Herbst JJ, Berenson MM, McCloskey DW, Wiser WC. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterology 1978;75:683-7.
18. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26-31.
19. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
20. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002;89:824-37.
21. Frank TS, Svoboda-Newman SM, Hsi ED. Comparison of methods for extracting DNA from formalin-fixed paraffin sections for nonisotopic PCR. Diagn Mol Pathol 1996;5:220-4.
22. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999;9:482-91.
23. Kraemer PS, Sanchez CA, Goodman GE, Jett J, Rabinovitch PS, Reid BJ. Flow cytometric enrichment for respiratory epithelial cells in sputum. Cytometry A 2004;60:1-7.
24. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
25. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-73.
26. Kusser WC, Levin DB, Glickman BW. Sensitive two-stage PCR of p53 genomic DNA exons 5-9. PCR Methods Appl 1993;2:250-2.
27. Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
28. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
29. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol 1998;93:332-5.
30. Overholt BF, Lightdale CJ, Wang K, et al. International, multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE): results of 24-month follow-up. Gastroenterology 2003;124:A-20.
31. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000;46:574-7.
32. Krishnadath KK, Wang KK, Tanigucni K, et al. p53 mutations in Barrett's esophagus predict poor response to photodynamic therapy. Gastroenterology 2001;120:A-413.
33. Csendes A, Burdiles P, Braghetto I, et al. Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus: the need for long-term subjective and objective follow-up. Ann Surg 2002;235:178-85.
34. Sampliner RE, Steinbronn K, Garewal HS, Riddell RH. Squamous mucosa overlying columnar epithelium in Barrett's esophagus in the absence of anti-reflux surgery. Am J Gastroenterol 1988;83:510-2.
35. Long JD, Orlando RC. Esophageal submucosal glands: structure and function. Am J Gastroenterol 1999;94:2818-24.
36. Li H, Walsh TN, O'Dowd G, Gillen P, Byrne PJ, Hennessy TP. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 1994;115:176-81.
37. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13:1205-9.